PF-04479745 is a research ligand developed by Pfizer. It is related to lorcaserin, and acts as a potent and selective agonist for the 5-HT2C receptor, with lower affinity and antagonist action at the related 5-HT2A and 5-HT2B receptor subtypes.[1]

PF-04479745
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • (9S)-2-benzyl-N,9-dimethyl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-d]azepin-4-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC17H22N4
Molar mass282.391 g·mol−1
3D model (JSmol)
  • C[C@H]1CNCCC2=C1N=C(N=C2NC)CC3=CC=CC=C3
  • InChI=1S/C17H22N4/c1-12-11-19-9-8-14-16(12)20-15(21-17(14)18-2)10-13-6-4-3-5-7-13/h3-7,12,19H,8-11H2,1-2H3,(H,18,20,21)/t12-/m0/s1
  • Key:IHHALLDEDARSAL-LBPRGKRZSA-N


References

edit
  1. ^ Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, et al. (June 2014). "Multiparameter optimization in CNS drug discovery: design of pyrimido[4,5-d]azepines as potent 5-hydroxytryptamine 2C (5-HT2C) receptor agonists with exquisite functional selectivity over 5-HT2A and 5-HT2B receptors". Journal of Medicinal Chemistry. 57 (12): 5258–69. doi:10.1021/jm5003292. PMID 24878222.